Strategies for improving detection of circulating tumor DNA using next generation sequencing

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer is a global health challenge.
• Liquid biopsy offers a non-invasive approach for cancer detection and monitoring.
• Circulating tumor DNA (ctDNA) in cell-free DNA (cfDNA) from plasma is a key biomarker.

Purpose of the Study:

• To review the applications of cfDNA and ctDNA in oncology.
• To discuss advancements in Next-Generation Sequencing (NGS) for ctDNA detection.
• To summarize NGS strategies in clinical and investigational cancer contexts.

Main Methods:

• Review of current literature on cfDNA and ctDNA.
• Analysis of techniques to enhance NGS sensitivity for low-frequency variants.
• Synthesis of findings from investigational and clinical studies using NGS.

Main Results:

• ctDNA analysis in cfDNA aids in early diagnosis, treatment selection, resistance monitoring, and understanding tumor heterogeneity.
• Low ctDNA frequencies necessitate highly sensitive detection methods.
• Optimized NGS techniques show potential for improved ctDNA variant identification.

Conclusions:

• Liquid biopsy and ctDNA analysis represent a significant advancement in cancer management.
• Further refinement of NGS technologies is essential for maximizing the clinical utility of ctDNA.
• NGS strategies are increasingly valuable in both research and clinical oncology settings.